Wall Street Zen Upgrades Astrana Health (NASDAQ:ASTH) to Buy

by · The Markets Daily

Astrana Health (NASDAQ:ASTH – Get Free Report) was upgraded by stock analysts at Wall Street Zen from a “hold” rating to a “buy” rating in a research note issued to investors on Saturday.

A number of other analysts also recently weighed in on the stock. TD Cowen upped their price target on shares of Astrana Health from $45.00 to $50.00 and gave the stock a “buy” rating in a report on Tuesday, July 14th. Robert W. Baird set a $45.00 price objective on shares of Astrana Health in a research note on Friday, May 8th. Needham & Company LLC boosted their price objective on shares of Astrana Health from $30.00 to $41.00 and gave the company a “buy” rating in a research report on Friday, May 8th. BTIG Research upped their target price on Astrana Health from $50.00 to $65.00 and gave the stock a “buy” rating in a research note on Tuesday, July 14th. Finally, Weiss Ratings raised Astrana Health from a “hold (c-)” rating to a “hold (c)” rating in a report on Monday, June 1st. Seven research analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $48.29.

View Our Latest Stock Analysis on ASTH

Astrana Health Price Performance

Shares of NASDAQ ASTH opened at $35.76 on Friday. The stock has a market capitalization of $1.99 billion, a PE ratio of 43.61 and a beta of 0.87. The company has a debt-to-equity ratio of 1.05, a current ratio of 1.23 and a quick ratio of 1.35. The business has a fifty day moving average price of $41.36 and a two-hundred day moving average price of $32.50. Astrana Health has a fifty-two week low of $18.08 and a fifty-two week high of $51.60.

Astrana Health (NASDAQ:ASTH – Get Free Report) last released its earnings results on Thursday, May 7th. The company reported $0.74 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.29 by $0.45. The company had revenue of $965.10 million for the quarter, compared to analyst estimates of $949.21 million. Astrana Health had a return on equity of 10.30% and a net margin of 1.05%.Astrana Health’s quarterly revenue was up 55.6% on a year-over-year basis. During the same period in the prior year, the firm posted $0.42 EPS. As a group, equities analysts predict that Astrana Health will post 1.18 earnings per share for the current fiscal year.

Institutional Trading of Astrana Health

A number of hedge funds have recently made changes to their positions in the company. Signaturefd LLC raised its holdings in Astrana Health by 57.9% in the 4th quarter. Signaturefd LLC now owns 1,058 shares of the company’s stock valued at $26,000 after buying an additional 388 shares during the last quarter. Strs Ohio bought a new position in Astrana Health during the 4th quarter worth $40,000. Tower Research Capital LLC TRC raised its position in Astrana Health by 323.3% during the 2nd quarter. Tower Research Capital LLC TRC now owns 4,605 shares of the company’s stock worth $115,000 after purchasing an additional 3,517 shares during the last quarter. State of Wyoming acquired a new position in Astrana Health during the 2nd quarter worth about $132,000. Finally, Los Angeles Capital Management LLC acquired a new position in Astrana Health during the 4th quarter worth about $228,000. 52.77% of the stock is owned by institutional investors and hedge funds.

More Astrana Health News

Here are the key news stories impacting Astrana Health this week:

  • Positive Sentiment: Adjusted earnings exceeded expectations. Astrana Health reported non-GAAP earnings of $0.40 per share, up from $0.19 a year earlier and above the $0.31 consensus estimate. A separate report cited $0.80 in EPS versus a $0.34 estimate, reflecting differences between reported and adjusted measures. ASTH Q2 Earnings Top Estimates
  • Positive Sentiment: Revenue continued to grow rapidly. Second-quarter revenue reached approximately $972.5 million, an increase of 48.5% year over year. Management and analysts highlighted operating leverage, technology investments and artificial intelligence initiatives as potential drivers of future profitability. ASTH Q2 Deep Dive
  • Positive Sentiment: Third-quarter revenue guidance points to continued expansion. Astrana Health forecast revenue of $1.00 billion to $1.03 billion for the third quarter, supporting expectations for sustained growth. ASTH Third-Quarter Revenue Guidance
  • Neutral Sentiment: Full-year revenue guidance was maintained at $3.8 billion to $4.1 billion. The midpoint is broadly consistent with the roughly $4.0 billion analyst consensus, suggesting no major change to the outlook. Astrana Health Second-Quarter Results
  • Negative Sentiment: Quarterly revenue was below expectations. Revenue of approximately $972.5 million trailed the $985.6 million consensus estimate. Astrana Health also continues to operate with a thin net margin, making execution and cost control important to the stock’s valuation. Astrana Health Earnings Report

About Astrana Health

(Get Free Report)

Astrana Health, Inc, Inc, a physician-centric technology-powered healthcare management company, provides medical care services in the United States. It operates through three segments: Care Partners, Care Delivery, and Care Enablement. The company is leveraging its proprietary population health management and healthcare delivery platform, operates an integrated, value-based healthcare model which empowers the providers in its network to deliver care to its patients. It offers care coordination services to patients, families, primary care physicians, specialists, acute care hospitals, alternative sites of inpatient care, physician groups, and health plans.

Further Reading